List of Progress in Hematology "Review Series" 2021-2022

*****2022*****

Epigenetics in lymphocyte and lymphoma: EZH2 as an easy-to-access therapeutic target?, (Edited by Koji Kato)

1. Kato K. Guest Editorial: Epigenetics in lymphocyte and lymphoma: EZH2 as an easy-to-access therapeutic target? Int J Hematol. 2022; 116:819-20.
   https://link.springer.com/article/10.1007/s12185-022-03472-z

2. Ennishi D. Biological and clinical significance of epigenetic alterations in B-cell lymphomas Int J Hematol. 2022; 116:821-7.
   https://link.springer.com/article/10.1007/s12185-022-03461-2

3. Yamagishi M. The role of epigenetics in T-cell lymphoma Int J Hematol. 2022; 116:828-36.
   https://link.springer.com/article/10.1007/s12185-022-03470-1

4. Wang Y, Bui T, Zhang Y. The pleiotropic roles of EZH2 in T-cell immunity and immunotherapy. Int J Hematol. 2022; 116:837-45.
   https://link.springer.com/article/10.1007/s12185-022-03466-x

Prevention and management of relapse after allogeneic hematopoietic cell transplantation in hematological malignancies (Edited by Daigo Hashimoto)

1. Hashimoto D. Guest editorial: prophylaxis and treatment of relapse after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2022; 116:307-8.
   https://link.springer.com/article/10.1007/s12185-022-03407-8

2. Ito A, Kim S-W, Fukuda T. Anti-programmed cell death-1 monoclonal antibody therapy before or after allogeneic hematopoietic cell transplantation for classic Hodgkin lymphoma: a literature review. Int J Hematol. 2022; 116:309-14. https://link.springer.com/article/10.1007/s12185-022-03391-z

3. Cao X-Y, Li J-J, Lu P-H, Liu K-Y, Efficacy and safety of CD19 CAR-T cell therapy for acute lymphoblastic leukemia patients relapsed after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2022; 116:315-29. https://link.springer.com/article/10.1007/s12185-022-03398-6

4. Kreidieh F, Dalle IA, Moukalled N, El-Cheikh J, Brissot E, Mohty M, et al. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment. Int J Hematol. 2022; 116:330-40. https://link.springer.com/article/10.1007/s12185-022-03416-7

5. Biavasco F, Zeiser R. FLT3-inhibitor therapy for prevention and treatment of relapse after allogeneic hematopoietic cell transplantation. Int J Hematol. 2022; 116:341-50. https://link.springer.com/article/10.1007/s12185-022-03352-6

The path from stem cells to red blood cells (Edited by Hideo Harigae)

1. Harigae H. The path from stem cells to red blood cells. Int J Hematol. 2022; 116:160-2. https://link.springer.com/article/10.1007/s12185-022-03413-w

2. Socolovsky M. The role of specialized cell cycles during erythroid lineage development: insights from single-cell RNA

sequencing. Int J Hematol. 2022; 116:163-73.
https://link.springer.com/article/10.1007/s12185-022-03406-9

3. Liao R, Bresnick EH. Heme as a differentiation-regulatory transcriptional cofactor. Int J Hematol. 2022; 116:174-81.
https://link.springer.com/article/10.1007/s12185-022-03404-x

4. Camaschella C, Pagani A, Silvestri L, Nai A. The mutual crosstalk between iron and erythropoiesis. Int J Hematol. 2022; 116:182-91.
https://link.springer.com/article/10.1007/s12185-022-03384-y

5. Soboleva S, Miharada K. Induction of enucleation in primary and immortalized erythroid cells. Int J Hematol. 2022; 116:192-8.
https://link.springer.com/article/10.1007/s12185-022-03386-w
.

Current status and future perspectives of allogeneic hematopoietic cell transplantation for non-malignant diseases (Edited by Katsutsugu Umeda)

1. Umeda K. Guest editorial: current status and future perspectives of allogeneic hematopoietic cell transplantation for non-malignant diseases. Int J Hematol. 2022; 116:5-6.
https://link.springer.com/article/10.1007/s12185-022-03366-0

2. Nishimura A, Miyamoto S, Imai K. Morio T. Conditioning regimens for inborn errors of immunity: current perspectives and future strategies. Int J Hematol. 2022; 116:7-15.
https://link.springer.com/article/10.1007/s12185-022-03389-7

3. Sakaguchi H. Yoshida N. Recent advances in hematopoietic cell transplantation for inherited bone marrow failure syndromes. Int J Hematol. 2022; 116:16-27.
https://link.springer.com/article/10.1007/s12185-022-03362-4

4. Yabe H. Allogeneic hematopoietic stem cell transplantation for inherited metabolic disorders. Int J Hematol. 2022; 116:28-40.
https://link.springer.com/article/10.1007/s12185-022-03383-z

5. Umeda K. Unresolved issues in allogeneic hematopoietic cell transplantation for non-malignant diseases. Int J Hematol. 2022; 116:41-7.
https://link.springer.com/article/10.1007/s12185-022-03361-5

Novel technologies and innovative treatments in multiple myeloma (Edited by Hiroyuki Takamatsu)

1. Takamatsu H. Guest Editorial: Innovation will be a bridge to cure in patients with multiple myeloma? Int J Hematol. 2022; 115:760-1.
https://link.springer.com/article/10.1007/s12185-022-03371-3

2. Hanamura I. Multiple myeloma with high-risk cytogenetics and its treatment approach. Int J Hematol. 2022; 115:762-77.
https://link.springer.com/article/10.1007/s12185-022-03353-5

3. Terao T, Matsue K. Progress of modern imaging modalities in multiple myeloma. Int J Hematol. 2022; 115:778-89.
https://link.springer.com/article/10.1007/s12185-022-03360-6

4. Murray DL. Bringing mass spectrometry into the care of patients with multiple myeloma. Int J Hematol. 2022; 115: 790- 8. https://link.springer.com/article/10.1007/s12185-022-03364-2

5. Ohmine K, Uchibori R. Novel immunotherapies in multiple myeloma. Int J Hematol. 2022; 115:799-810. https://link.springer.com/article/10.1007/s12185-022-03365-1

Clinical aspects and treatment options in myeloproliferative neoplasms (Edited by Akihiro Gotoh)

1. Akihiro G. Philadelphia chromosome-negative myeloproliferative neoplasms: clinical aspects and treatment options. Int J Hematol. 2022;115: 616–8. https://link.springer.com/article/10.1007/s12185-022-03344-6

2. Gagelmann N. Kröger N. Improving allogeneic stem cell transplantation in myelofibrosis. Int J Hematol. 2022; 115: 619–25. https://link.springer.com/article/10.1007/s12185-022-03340-w

3. Loscocco GG, Vannucchi AM. Role of JAK inhibitors in myeloproliferative neoplasms: current point of view and perspectives. 2022; 115: 626-44. https://link.springer.com/article/10.1007/s12185-022-03335-7

4. Tremblay D, Mesa R. Novel treatments for myelofibrosis: beyond JAK inhibitors. Int J Hematol. 2022; 115: 645- 58. https://link.springer.com/article/10.1007/s12185-022-03299-8

5. Edahiro Y. Treatment options and pregnancy management for patients with PV and ET. Int J Hematol. 2022; 115: 659- 71.
https://link.springer.com/article/10.1007/s12185-022-03336-6

*****2021*****

Advances in diagnosis and treatment of disseminated intravascular coagulation (Edited by Hidesaku Asakura)

1. Asakura H. Diversity of disseminated intravascular coagulation and selection of appropriate treatments. Int J Hematol. 2021;113:10-4.
https://link.springer.com/article/10.1007/s12185-020-03030-5

2. Yamada S, Asakura H. Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations. Int J Hematol. 2021;113:15-23.
https://link.springer.com/article/10.1007/s12185-020-03028-z

3. Iba T, Connors JM, Nagaoka I, Levy JH. Recent advances in the research and management of sepsis-associated DIC. Int J Hematol. 2021;113:24-33
https://link.springer.com/article/10.1007/s12185-020-03053-y

4. Ikezoe T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. Int J Hematol. 2021;113:34-44.
https://link.springer.com/article/10.1007/s12185-020-02992-w

5. Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. Int J Hematol.

2021;113:45-57.
https://link.springer.com/article/10.1007/s12185-020-03029-y

Aiming for the final goal (Edited by Shinya Kimura)

1. Kimura S. Evolution of CML treatment. Int J Hematol. 2021; 113:622-3.
https://link.springer.com/article/10.1007/s12185-021-03128-4

2. Morita K, Sasaki K. Current status and novel strategy of CML. Int J Hematol. 2021; 113:624-31.
https://link.springer.com/article/10.1007/s12185-021-03127-5

3. Lee H, Basso IN, Kim DDH. Target spectrum of the BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia. Int J Hematol. 2021; 113:632-41.
https://link.springer.com/article/10.1007/s12185-021-03126-6

4. Ureshino H. Treatment-free remission and immunity in chronic myeloid leukemia. Int J Hematol. 2021; 113:642-7.
https://link.springer.com/article/10.1007/s12185-021-03117-7

5. Naka K. New routes to eradicating chronic myelogenous leukemia stem cells by targeting metabolism. Int J Hematol. 2021; 113:648-55.
https://link.springer.com/article/10.1007/s12185-021-03112-y

CAR-T cell therapy, Now the time for the next！(Edited by Hiroshi Fujiwara)

1. Fujiwara H. Efforts to maximize the potential of CAR-T therapy for cancer, from T-bodies to CAR-immune cells. Int J Hematol. 2021;114:529-31. https://link.springer.com/article/10.1007/s12185-021-03213-8

2. Lundh S, Maji S, Melenhorst JJ. Next-generation CAR T cells to overcome current drawbacks. Int J Hematol. 2021; 114:532-43. https://link.springer.com/article/10.1007/s12185-020-02923-9

3. Wang X, Diamond DJ, Forman SJ, Nakamura R. Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine. Int J Hematol. 2021; 114:544-53. https://link.springer.com/article/10.1007/s12185-021-03215-6

4. Biederstädt A, Rezvani K. Engineering the next generation of CAR-NK immunotherapies. Int J Hematol. 2021; 114:554-71. https://link.springer.com/article/10.1007/s12185-021-03209-4

5. Ueda T, Kaneko S. Induced pluripotent stem cell-derived natural killer cells gene-modified to express chimeric antigen receptor-targeting solid tumors. Int J Hematol. 2021; 114:572-9. https://link.springer.com/article/10.1007/s12185-020-02951-5